File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection

TitleSerum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection
Authors
KeywordsAmino acids
Bile acids
Chronic liver disease
Free fatty acids
Hepatitis B
Liver fibrosis
Metabolomics
Random forest
Issue Date2020
Citation
BMC Medicine, 2020, v. 18, n. 1, article no. 144 How to Cite?
AbstractBackground: Accurate and noninvasive diagnosis and staging of liver fibrosis are essential for effective clinical management of chronic liver disease (CLD). We aimed to identify serum metabolite markers that reliably predict the stage of fibrosis in CLD patients. Methods: We quantitatively profiled serum metabolites of participants in 2 independent cohorts. Based on the metabolomics data from cohort 1 (504 HBV associated liver fibrosis patients and 502 normal controls, NC), we selected a panel of 4 predictive metabolite markers. Consequently, we constructed 3 machine learning models with the 4 metabolite markers using random forest (RF), to differentiate CLD patients from normal controls (NC), to differentiate cirrhosis patients from fibrosis patients, and to differentiate advanced fibrosis from early fibrosis, respectively. Results: The panel of 4 metabolite markers consisted of taurocholate, tyrosine, valine, and linoelaidic acid. The RF models of the metabolite panel demonstrated the strongest stratification ability in cohort 1 to diagnose CLD patients from NC (area under the receiver operating characteristic curve (AUROC) = 0.997 and the precision-recall curve (AUPR) = 0.994), to differentiate fibrosis from cirrhosis (0.941, 0.870), and to stage liver fibrosis (0.918, 0.892). The diagnostic accuracy of the models was further validated in an independent cohort 2 consisting of 300 CLD patients with chronic HBV infection and 90 NC. The AUCs of the models were consistently higher than APRI, FIB-4, and AST/ALT ratio, with both greater sensitivity and specificity. Conclusions: Our study showed that this 4-metabolite panel has potential usefulness in clinical assessments of CLD progression in patients with chronic hepatitis B virus infection.
Persistent Identifierhttp://hdl.handle.net/10722/342746
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorXie, Guoxiang-
dc.contributor.authorWang, Xiaoning-
dc.contributor.authorWei, Runmin-
dc.contributor.authorWang, Jingye-
dc.contributor.authorZhao, Aihua-
dc.contributor.authorChen, Tianlu-
dc.contributor.authorWang, Yixing-
dc.contributor.authorZhang, Hua-
dc.contributor.authorXiao, Zhun-
dc.contributor.authorLiu, Xinzhu-
dc.contributor.authorDeng, Youping-
dc.contributor.authorWong, Linda-
dc.contributor.authorRajani, Cynthia-
dc.contributor.authorKwee, Sandi-
dc.contributor.authorBian, Hua-
dc.contributor.authorGao, Xin-
dc.contributor.authorLiu, Ping-
dc.contributor.authorJia, Wei-
dc.date.accessioned2024-04-17T07:05:57Z-
dc.date.available2024-04-17T07:05:57Z-
dc.date.issued2020-
dc.identifier.citationBMC Medicine, 2020, v. 18, n. 1, article no. 144-
dc.identifier.urihttp://hdl.handle.net/10722/342746-
dc.description.abstractBackground: Accurate and noninvasive diagnosis and staging of liver fibrosis are essential for effective clinical management of chronic liver disease (CLD). We aimed to identify serum metabolite markers that reliably predict the stage of fibrosis in CLD patients. Methods: We quantitatively profiled serum metabolites of participants in 2 independent cohorts. Based on the metabolomics data from cohort 1 (504 HBV associated liver fibrosis patients and 502 normal controls, NC), we selected a panel of 4 predictive metabolite markers. Consequently, we constructed 3 machine learning models with the 4 metabolite markers using random forest (RF), to differentiate CLD patients from normal controls (NC), to differentiate cirrhosis patients from fibrosis patients, and to differentiate advanced fibrosis from early fibrosis, respectively. Results: The panel of 4 metabolite markers consisted of taurocholate, tyrosine, valine, and linoelaidic acid. The RF models of the metabolite panel demonstrated the strongest stratification ability in cohort 1 to diagnose CLD patients from NC (area under the receiver operating characteristic curve (AUROC) = 0.997 and the precision-recall curve (AUPR) = 0.994), to differentiate fibrosis from cirrhosis (0.941, 0.870), and to stage liver fibrosis (0.918, 0.892). The diagnostic accuracy of the models was further validated in an independent cohort 2 consisting of 300 CLD patients with chronic HBV infection and 90 NC. The AUCs of the models were consistently higher than APRI, FIB-4, and AST/ALT ratio, with both greater sensitivity and specificity. Conclusions: Our study showed that this 4-metabolite panel has potential usefulness in clinical assessments of CLD progression in patients with chronic hepatitis B virus infection.-
dc.languageeng-
dc.relation.ispartofBMC Medicine-
dc.subjectAmino acids-
dc.subjectBile acids-
dc.subjectChronic liver disease-
dc.subjectFree fatty acids-
dc.subjectHepatitis B-
dc.subjectLiver fibrosis-
dc.subjectMetabolomics-
dc.subjectRandom forest-
dc.titleSerum metabolite profiles are associated with the presence of advanced liver fibrosis in Chinese patients with chronic hepatitis B viral infection-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1186/s12916-020-01595-w-
dc.identifier.pmid32498677-
dc.identifier.scopuseid_2-s2.0-85086062312-
dc.identifier.volume18-
dc.identifier.issue1-
dc.identifier.spagearticle no. 144-
dc.identifier.epagearticle no. 144-
dc.identifier.eissn1741-7015-
dc.identifier.isiWOS:000540325700001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats